Tentative Exploration of Pharmacodynamic Substances: Pharmacological Effects, Chemical Compositions, and Multi-components Pharmacokinetic Characteristics of ESZWD in CHF-HKYd Rats

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 3

PMID 36186966

Authors

Li-Li Hong

Yan Zhao

Wei-Dong Chen

Chen-Yu Yang

Guo-Zhuan Li

Hong-Song Wang

Xiao-Yu Cheng

Affiliations

Soon will be listed here.

Abstract

The chemical components of Xin'an famous prescription Ershen Zhenwu Decoction (ESZWD) are still unclear. The results showed that ESZWD could significantly reduce left ventricular end diastolic diameter, decrease N-terminal pro-brain natriuretic peptide (NT-proBNP), angiotensinII, aldosterone, reactive oxygen species, and malondialdehyde, increase serum superoxide dismutase, while had no significant effect on inflammatory factors. Ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF-MS) analysis detected 30 prototype components in model rats' serum, mainly including alkaloids, saponins, terpenoids, tanshinones, phenols. UPLC-MS/MS successfully detected the pharmacokinetic parameters of four components, and correlation analysis shows that there are negative correlations between four compounds and serum NT-proBNP. Thirty components of ESZWD may play a therapeutic role in chronic heart failure with heart-kidney Yang deficiency (CHF-HKYd) by improving myocardial injury, reducing oxidative stress levels, and inhibiting activation of the RAAS system in rats. Salsolinol, aconitine, paeoniflorin, and miltrione are equipped with potential characteristics as pharmacodynamic substances for ESZWD in treating CHF-HKYd. Additionally, the constituents of ESZWD in CHF-HKYd rats are different from normal rats, which provided a reference for the selection of subjects for further study.

Citing Articles

Study on the Compositional Analysis, Extraction Process, and Hemostatic and Anti-Inflammatory Activities of - (Willd.) Extracts.

Kong F, Fang Z, Cui B, Gao J, Sun C, Zhang S Molecules. 2024; 29(9).

PMID: 38731410 PMC: 11085329. DOI: 10.3390/molecules29091918.

Salsolinol improves angiotensin II‑induced myocardial fibrosis via inhibition of LSD1 through regulation of the STAT3/Notch‑1 signaling pathway.

Zhang X, Shao Z, Ni Y, Chen F, Yu X, Wen J Exp Ther Med. 2023; 26(5):527.

PMID: 37869646 PMC: 10587875. DOI: 10.3892/etm.2023.12226.

Small molecule metabolites: discovery of biomarkers and therapeutic targets.

Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S Signal Transduct Target Ther. 2023; 8(1):132.

PMID: 36941259 PMC: 10026263. DOI: 10.1038/s41392-023-01399-3.

References

Chen J, Zhang J, Zhang X, Qi M, Shi M, Yang J . Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro. Toxicol Appl Pharmacol. 2017; 334:1-7. DOI: 10.1016/j.taap.2017.08.020. View

Wang M, Chen D, Chen L, Liu D, Zhao H, Zhang Z . Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/β-Catenin Pathway and Targeted Phosphorylation of smad3 Signaling. J Agric Food Chem. 2018; 66(8):1828-1842. DOI: 10.1021/acs.jafc.8b00099. View

Song W, Ma Y, Miao S, Yang R, Zhu Y, Shu D . Pharmacological actions of miltirone in the modulation of platelet function. Acta Pharmacol Sin. 2018; 40(2):199-207. PMC: 6329759. DOI: 10.1038/s41401-018-0010-1. View

Zhang X, Zhang P, An L, Sun N, Peng L, Tang W . Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Acta Pharm Sin B. 2020; 10(8):1397-1413. PMC: 7488361. DOI: 10.1016/j.apsb.2020.06.015. View

Mancini A, Vergani E, Bruno C, Olivieri G, Di Segni C, Silvestrini A . Oxidative stress as a possible mechanism underlying multi-hormonal deficiency in chronic heart failure. Eur Rev Med Pharmacol Sci. 2018; 22(12):3936-3961. DOI: 10.26355/eurrev_201806_15279. View

Spinarova M, Spinar J, Parenica J, Spinarova L, Malek F, Labr K . Prescription and dosage of RAAS inhibitors in patients with chronic heart failure in the FAR NHL registry. Vnitr Lek. 2019; 65(1):13-14. View

Hong L, Wang H, Cheng X, Zhang S, Zhao Y, Wang Q . Evaluation and Clinical Implication of Zhenwu Decoction on Seven Cytochrome P450 Enzyme in Chronic Heart Failure Rats. Curr Drug Metab. 2021; 22(9):746-755. DOI: 10.2174/1389200222666210701171047. View

Yang W, Qiao X, Li K, Fan J, Bo T, Guo D . Identification and differentiation of , , and by monitoring multiple diagnostic chemical markers. Acta Pharm Sin B. 2016; 6(6):568-575. PMC: 5071635. DOI: 10.1016/j.apsb.2016.05.005. View

Wang H, Gu J, Hou X, Chen J, Yang N, Liu Y . Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway. Biomed Pharmacother. 2016; 85:531-540. DOI: 10.1016/j.biopha.2016.11.061. View

10.

Hong L, Zhao Y, Yang C, Li G, Wang H, Chen W . Identification of chemical constituents in vitro and in vivo of Er Shen Zhenwu Decoction by utilizing ultra-high-performance liquid chromatography with quadrupole time-of-flight mass spectrometry. J Sep Sci. 2021; 44(24):4327-4342. DOI: 10.1002/jssc.202100624. View

11.

Li J, Zhang S, He D, Wang J, Li J . Paeoniflorin reduced the cardiotoxicity of aconitine in h9c2 cells. J Biol Regul Homeost Agents. 2019; 33(5):1425-1436. DOI: 10.23812/19-257A. View

12.

Wu F, Ye B, Wu X, Lin X, Li Y, Wu Y . Paeoniflorin on Rat Myocardial Ischemia Reperfusion Injury of Protection and Mechanism Research. Pharmacology. 2019; 105(5-6):281-288. DOI: 10.1159/000503583. View

13.

Romuk E, Wojciechowska C, Jachec W, Zemla-Woszek A, Momot A, Buczkowska M . Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxid Med Cell Longev. 2019; 2019:9246138. PMC: 6803743. DOI: 10.1155/2019/9246138. View

14.

Wang N, Wang J, Tan H, Wang Y, Gao Y, Ma Z . [Aconitine ameliorates cardiomyocyte hypertrophy induced by angiotensin Ⅱ]. Zhongguo Zhong Yao Za Zhi. 2019; 44(8):1642-1647. DOI: 10.19540/j.cnki.cjcmm.20190117.002. View

15.

Ma D, Xu T, Cai G, Wu X, Lei Z, Liu X . Effects of ivabradine hydrochloride combined with trimetazidine on myocardial fibrosis in rats with chronic heart failure. Exp Ther Med. 2019; 18(3):1639-1644. PMC: 6676191. DOI: 10.3892/etm.2019.7730. View

16.

Rorth R, Jhund P, Yilmaz M, Kristensen S, Welsh P, Desai A . Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020; 13(2):e006541. DOI: 10.1161/CIRCHEARTFAILURE.119.006541. View

17.

Zhang L, Zhang H, Li X, Jia B, Yang Y, Zhou P . Miltirone protects human EA.hy926 endothelial cells from oxidized low-density lipoprotein-derived oxidative stress via a heme oxygenase-1 and MAPK/Nrf2 dependent pathway. Phytomedicine. 2016; 23(14):1806-1813. DOI: 10.1016/j.phymed.2016.11.003. View

18.

Reina-Couto M, Afonso J, Carvalho J, Morgado L, Ronchi F, Leite A . Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment. Biomed Pharmacother. 2020; 133:110938. DOI: 10.1016/j.biopha.2020.110938. View

19.

Setsuta K, Seino Y, Ogawa T, Ohtsuka T, Seimiya K, Takano T . Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J. 2004; 68(8):747-50. DOI: 10.1253/circj.68.747. View

20.

McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur Heart J. 2012; 33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. View